Advertisement
Advertisement
TRDA
Entrada Therapeutics, Inc. Common Stock
7.32
USDSponsored
+0.20
+2.81%
May 13, 16:00 UTC -4
Closed
Pre-Market
7.17
-0.15
-1.98%
TRDA Earnings Reports
Positive Surprise Ratio
TRDA beat 10 of 19 last estimates.
53%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$419.66K
/-$1.08
Implied change from Q1 26 (Revenue/ EPS)
-52.04%
/+13.68%
Implied change from Q2 25 (Revenue/ EPS)
-78.48%
/+3.85%
Entrada Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, TRDA reported earnings of -0.95 USD per share (EPS) for Q1 26, beating the estimate of -1.05 USD, resulting in a 10.17% surprise. Revenue reached 875.00 thousand, compared to an expected 1.42 million, with a -38.43% difference. The market reacted with a -57.27% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -1.08 USD, with revenue projected to reach 419.66 thousand USD, implying an increase of 13.68% EPS, and decrease of -52.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Entrada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Entrada Therapeutics, Inc. Common Stock reported EPS of -$0.95, beating estimates by 10.17%, and revenue of $875.00K, -38.43% below expectations.
How did the market react to Entrada Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -57.27%, changed from $16.03 before the earnings release to $6.85 the day after.
When is Entrada Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Entrada Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Entrada Therapeutics, Inc. Common Stock is expected to report EPS of -$1.08 and revenue of $419.66K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement